← Back to Clinical Trials
Recruiting Phase 2 NCT06049355

NCT06049355 EMBRACE: Exercising Together

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06049355
Status Recruiting
Phase Phase 2
Sponsor OHSU Knight Cancer Institute
Condition Breast Carcinoma
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2024-04-18
Primary Completion 2028-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Exercise InterventionBiospecimen CollectionEducational Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 400 participants in total. It began in 2024-04-18 with a primary completion date of 2028-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This phase II trial tests how well an exercise intervention, Exercising Together, works in preventing declines in physical and mental health in couples during radiation treatment for cancer. Treatments for cancer can cause side effects such as fatigue as well as strain on relationships. Exercising Together is a partnered exercise program that adds communication, collaboration and support between partners during exercise to fortify the relationship and amplify the benefits of physical training. Exercising Together program may be effective on the mental and physical health of couples during radiation treatment for cancer.

Eligibility Criteria

Inclusion Criteria: * INTERVENTION (SURVIVORS) INCLUSION * Histologically confirmed prostate cancer or breast cancer without evidence of metastatic disease * Confirmed by review of the electronic medical record (EMR) and subsequently recorded in Survivor Health History. In cases where the EMR isn't clear, their Oregon Health \& Science University (OHSU) provider will be contacted for confirmation. For non-OHSU patients, we'll initially collect their cancer health history by a self-report questionnaire and confirm when we receive the survivor's outside medical record (through a signed Release of Information) * Scheduled to receive radiation therapy for curative intent * Confirmed by review of the EMR and subsequently recorded in Survivor Health History. In cases where the EMR isn't clear, their OHSU provider will be contacted for confirmation/ For non-OHSU patients, we'll initially collect their cancer health history by a self-report questionnaire and confirm when we receive the survivor's outside medical record (through a signed Release of Information) * Co-residing with an intimate partner or spouse who is willing to participate * Confirmed by self-report on the Demographic Questionnaire * INTERVENTION (SURVIVORS AND PARTNERS) INCLUSION * 18 years of age and older * For survivors: confirmed by review of the date of birth as documented in the Electronic Medical Record (EMR) and subsequently recorded in Survivor Health History. For non-OHSU patients, we'll collect their age by self-report on the Survivor Health History * For partners: confirmed by self-report on the Health History Questionnaire * \< 2 structured strength training sessions for less than 30 minutes per week in the last month * Confirmed by self-report on Health History Questionnaire * Home internet sufficient for videoconferencing * Confirmed by staff review of Internet Connectivity Screening Guide with the participants and outcome recorded in a CRF * Signed informed consent * Confirmed by completion of e-Consent in REDCap * Willing to be randomized into either study arm and adhere to study protocol * Confirmed verbally with the participant and response documented in the Participant Tracking database * IMPLEMENTATION INCLUSION * Be one of these key stakeholders: patient, spouse/partner, healthcare providers, or administrator * Verbal informed consent following receipt of an Information Sheet Exclusion Criteria: * INTERVENTION (SURVIVORS AND PARTNERS) EXCLUSION * Cognitive difficulties that preclude answering the survey questions, participating in the exercise classes or performance tests, or providing informed consent * In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the Principal Investigator, Kerri Winters-Stone * A medical condition, movement or neurological disorder, or medication use that contraindicates participation in moderate intensity exercise. Specific contraindications include the following: poorly controlled diabetes, recent cardiac event, neuromuscular disease, untreated orthostatic hypertension, recent surgery, acute hernia, acute rheumatoid arthritis, severe memory disorders, severe balance disorder, inability to ambulate without a walker or wheelchair, inability to stand for 3 minutes, severe hearing or vision problem * Confirmed by a combination of reviewing the EMR, self-report on the Health History Questionnaire, Charlson Comorbidity Index questionnaire, and/or by physician clearance. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible. For Spouse/Partner: must answer \'No\' to American College of Sports Medicine pre-participation screening questions. If spouse/partner answers \'Yes\' to either question they may be required to obtain physician clearance prior to becoming eligible. Physician clearance may also be requested at the discretion of the principal investigator.

Contact & Investigator

Central Contact

Carolyn Guidarelli

✉ exercise@ohsu.edu

📞 503-494-0444

Principal Investigator

Kerri Winters-Stone

PRINCIPAL INVESTIGATOR

OHSU Knight Cancer Institute

Frequently Asked Questions

Who can join the NCT06049355 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06049355 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT06049355 currently recruiting?

Yes, NCT06049355 is actively recruiting participants. Contact the research team at exercise@ohsu.edu for enrollment information.

Where is the NCT06049355 trial being conducted?

This trial is being conducted at Portland, United States.

Who is sponsoring the NCT06049355 clinical trial?

NCT06049355 is sponsored by OHSU Knight Cancer Institute. The principal investigator is Kerri Winters-Stone at OHSU Knight Cancer Institute. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology